---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-072603"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T05:28:42.593469+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tivic Health Q1 revenue drops 79% to $70K; pursues Entolimod and ncVNS pipeline

## Summary
- Revenue fell 79% YoY to $70K; net loss unchanged at $1.5M. Cash $669K vs $2.0M at year-end.
- Licensed Phase III TLR5 agonist Entolimod for ARS; began GMP manufacturing validation for BLA.
- Briefed White House and FDA on defense applications; secured $25M equity line and $8.4M purchase agreement.
- Expanded ncVNS optimization study; regained Nasdaq compliance via 1-for-17 reverse split in March.
- Gross margin improved to 72% (vs 50% a year ago) but operating expenses flat at $1.6M.

## SEC filing metadata
- accession: 0000950170-25-072603
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000095017025072603/0000950170-25-072603-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000095017025072603/tivc-20250515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-072603
- JSON: https://secwatch.observer/filing/0000950170-25-072603.json
- Plain text: https://secwatch.observer/filing/0000950170-25-072603.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.